[Reducing the dosage by new technology].
Steinhorst
M
M
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects; D001284:Atrophy; D002675:Child, Preschool; D017321:Clinical Trials, Phase I as Topic; D004311:Double-Blind Method; D004337:Drug Carriers; D004485:Eczema / Q000188:drug therapy; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D009824:Ointments; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012867:Skin / Q000187:drug effects / Q000473:pathology; D013810:Therapeutic Equivalency; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects
D000893:Anti-Inflammatory Agents; D004337:Drug Carriers; D005938:Glucocorticoids; D009824:Ointments; D014222:Triamcinolone Acetonide
Dosisreduktion durch neue technologie.